SAB Biotherapeutics, Inc. SABS

3.29 (0.06) (1.79%) as of 25 Sep
Market cap
$304.8M
P/E
0.0×
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '17
P/E ratio
— 0.00 0.00 0.00 0.00 0.00 —
P/S ratio
— 21.57 17.26 1.18 3.51 0.00 —
P/FCF ratio
— 0.00 0.00 0.00 0.00 0.00 —
P/Operating CF
— (3.68) (2.87) (18.19) (43.77) (150,140.83) —
P/B ratio
— 1.35 0.67 0.91 5.54 93,838.02 —
Price to Tangible BV
— 1.35 0.67 0.91 5.54 93,838.02 —
EV/Sales
— 10.83 (6.47) 0.73 2.92 0.00 —
EV/EBITDA
— 0.00 0.42 0.00 0.00 0.00 —
EV/Operating CF
— (0.51) 0.58 (0.74) 89.45 0.00 —
EV/FCF
— (0.51) 0.57 (0.68) (19.84) 0.00 —
Quick Ratio
9.13 2.61 5.23 1.37 1.80 3.00 —
Current Ratio
9.46 2.98 5.45 1.47 1.90 3.11 —
Net Debt/EBITDA
2.03 0.46 1.55 0.42 3.05 (0.40) —
Debt/Assets
1.81% 7.41% 4.07% 8.19% 4.64% 7.24% 0.00%
Debt/Equity
0.02 0.13 0.06 0.13 0.10 0.11 —
Asset Turnover
0.00 0.02 0.03 0.36 0.88 1.95 —
Operating CF/Net income
(10.51) 1.01 0.60 1.25 (0.12) 0.50 —
Capex/Depreciation
(0.31) (0.07) (0.04) (0.63) (6.62) (23.21) —
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 —
ROE
4.80% (81.92%) (95.51%) (53.85%) (44.21%) 51.88% —
ROA
3.93% (53.23%) (62.58%) (28.39%) (24.91%) 71.17% —
ROIC
(52.73%) (316.08%) (573.17%) (89.55%) (302.49%) 42.13% —
Return on Tangible Assets
4.11% (109.38%) (62.21%) (61.74%) (35.68%) 52.61% —
Average Days of Receivables
0.00 15.18 0.00 84.85 48.03 135.92 —
Research and Development Expense of Revenue
0.00% 2,287.64% 737.61% 152.44% 93.93% 50.52% —
Selling, General and Administrative Expense of Revenue
0.00% 1,057.27% 1,062.94% 68.54% 28.07% 12.26% —
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 222.46% 108.25% 11.19% 3.80% 2.35% —
Graham Net Nets
— 0.16 0.83 0.08 0.04 0.00 —
Graham Number
— 0.00 0.00 0.00 0.00 0.00 —
Earnings Yield
— (97.10%) (110.63%) (65.84%) (8.03%) 0.00% —
Free Cash Flow Yield
— (98.65%) (65.39%) (90.31%) (4.19%) 0.00% —
Revenue per Share
0.00 0.14 0.41 5.49 22.27 21.75 —
Operating CF per Share
(2.32) (3.70) (4.55) (5.39) 0.73 3.94 —
Capex per Share
(0.05) (0.04) (0.03) (0.48) (4.00) (5.01) —
Free Cash Flow per Share
(2.37) (3.74) (4.58) (5.87) (3.28) (1.07) —
Cash per Share
5.00 2.24 10.24 3.46 14.46 4.97 —
Shareholders Equity per Share
7.84 2.80 10.38 7.14 14.10 15.36 —
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 —
Book value per Share
7.84 2.80 10.38 7.14 14.10 15.36 —
Free Cash Flow
(45.71) (34.63) (25.27) (25.55) (8.96) (2.72) —
Working Capital
90.37 15.81 48.09 7.10 23.74 23.39 —
Capital Expenditures
(0.93) (0.34) (0.15) (2.09) (10.94) (12.72) —
Net Current Asset Value
79.74 5.57 32.27 2.25 7.60 16.92 —
EV/EBIT
— 0.00 0.38 0.00 0.00 0.00 —
Capex to Sales
0.00 0.26 0.07 0.09 0.18 0.23 —
Net Profit Margin
0.00% (2,579.05%) (1,884.49%) (78.40%) (28.16%) 36.42% —
Price to Operating Income
— 0.00 0.00 0.00 0.00 0.00 —
Other line items
Depreciation/Fixed assets
0.22 0.30 0.19 0.14 0.07 0.04 —
Cash ROIC
(23.12%) (99.31%) (38.25%) (92.91%) (27.28%) (8.69%) —
Accounts Receivable Turnover
0.00 0.47 0.00 3.52 4.26 3.87 —
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 —
Inventory Turnover
— — — 0.00 0.00 0.00 —
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 —
Days of Inventory on Hand
— — — 0.00 0.00 0.00 —
Average Receivables
0.50 2.81 — 6.78 14.29 14.29 —
Average Payables
2.42 1.32 2.31 4.07 5.92 5.92 —
Average Assets
108.50 64.07 67.42 66.02 68.84 28.27 —
Average Common Equity
88.73 41.63 44.18 34.80 38.78 38.78 —

Fold the line items

Columns are period end dates